ArticleFrontiers in immunology2026

Rational design of D(+)-biotin-conjugated resorcinol dibenzyl ethers as tumor-targeted PD-L1 inhibitors for precision cancer immunotherapy.

Jing-Jing Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.